Search Clinical Trials in the European Union

Duration
≤5 visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
101-120 of 525 trials

Talquetamab: Reducing Oral Side Effects

We are testing ways to lessen taste changes caused by talquetamab in patients undergoing treatment. The goal is to find effective methods to improve the experience for those affected.

Multiple Myeloma>2 yearsEfficacy phase (II)≤5 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteInternal MedicineOncology

Breast Cancer Treatment: Chemotherapy vs. Endocrine Therapy

We are studying the effectiveness of chemotherapy compared to endocrine therapy for women with ER-positive HER2-negative metastatic breast cancer. This trial focuses on patients with specific health markers to determine the best treatment option.

Metastatic Breast Cancer>2 yearsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesOncology

Advanced Head and Neck Cancer: Volrustomig Treatment Study

We are studying whether volrustomig is safe and effective for adults with advanced head and neck cancer who have recently completed chemoradiotherapy without surgery. This trial compares the treatment to observation to see which approach may help patients more.

Unresected Locally Advanced Head and Neck Squamous Cell CarcinomaConfirmation phase (III)≤5 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncologyOtolaryngology

Major Depressive Disorder: NMRA-335140 Study

We are testing a new oral medication for adults with major depressive disorder to see if it helps improve their symptoms compared to a placebo. The study will measure changes in mood and daily functioning over six weeks.

Major Depressive Disorder≤3 monthsConfirmation phase (III)≤5 visitsInvestigational MedicinesCost ReimbursementPartially RemotePsychiatry

Uterine Leiomyosarcoma: Post-Operative Chemotherapy Study

We are investigating whether adding chemotherapy after surgery helps patients with high-risk localized uterine leiomyosarcoma avoid relapse. This study compares the new treatment approach to standard observation care.

Uterine LeiomyosarcomaEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesGynecology and ObstetricsOncology

Preventing Diabetes After Kidney Transplant: GLP-1 Medication Study

We are testing whether GLP-1 receptor agonists can help reverse metabolic syndrome in patients on the kidney transplant waiting list. This study will evaluate changes in health and safety over 3 to 6 months.

Metabolic Syndrome in Kidney Transplant Patients3-6 monthsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesEndocrinologyNephrology

Liver Transplant: Low-Dose Arginine-Vasopressin Study

We are investigating whether low-dose arginine-vasopressin can reduce kidney injury after liver transplantation. This study aims to improve recovery and outcomes for transplant patients.

Acute Kidney InjuryLiver Transplantation≤3 monthsConfirmation phase (III)≤5 visitsNo PlaceboInvestigational MedicinesHepatologyNephrology

Mycobacterium abscessus: Optimizing Lung Disease Treatment

We are studying the best treatment options for lung disease caused by Mycobacterium abscessus. Our goal is to see how well these treatments clear the infection and how well patients tolerate them.

Mycobacterium Abscessus Infection1-2 yearsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesPartially RemoteInfectious DiseasesPulmonology

Schizophrenia: Intensified Treatment Study

We are investigating whether a six-week intensified medication plan helps individuals with schizophrenia who didn't respond to their first treatment. The study looks at changes in symptoms, functioning, and overall well-being compared to standard care.

Schizophrenia and Related Disorders≤3 monthsMonitoring phase (IV)≤5 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemotePsychiatry

Bipolar Depression: New Treatment Approach

We are investigating whether a six-week intensified medication plan helps people with bipolar depression who didn't respond to their first treatment. We’ll compare this new approach to standard care to see which is more effective.

Bipolar Depression≤3 monthsConfirmation phase (III)≤5 visitsNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemotePsychiatry

Alzheimer's Disease in Down Syndrome: Sleep and Temperature Study

We are examining how sleep disorders and body temperature changes may indicate the progression of Alzheimer's disease in people with Down syndrome. This research could help identify early signs of the disease.

Down SyndromeAlzheimer's Disease>2 yearsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesCost ReimbursementNeurologyPsychiatry

Major Depressive Disorder: New Treatment Approach

We are studying whether a six-week intensified medication treatment helps people with major depressive disorder who didn't respond to their first treatment. The goal is to see if this new approach improves symptoms and overall well-being compared to standard care.

Major Depressive Disorder≤3 monthsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemotePsychiatry

Niraparib: Long-Term Safety Study for Cancer Patients

We are evaluating the long-term safety and tolerability of niraparib for patients who have previously completed a study and are deemed to benefit from continued treatment. This study helps us understand how well the medication can be tolerated over time.

Advanced Ovarian, Breast, or Prostate CancerEfficacy phase (II)≤5 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteOncology

Ocular Myasthenia Gravis: Corticosteroids and Rituximab Treatment

We are studying whether immediate corticosteroid therapy combined with rituximab can help prevent worsening symptoms in patients with ocular myasthenia gravis. This trial looks at various health outcomes over two years.

Myasthenia Gravis6-12 monthsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesNeurologyRheumatology

HER2-Low Breast Cancer: Trastuzumab-Deruxtecan Study

We are studying a new treatment for patients with HER2-low breast cancer and brain metastases to see if it helps shrink tumors and improve quality of life. This trial will also look at safety and how well patients tolerate the treatment.

HER2-Low Breast Cancer with Brain Metastases1-2 yearsEfficacy phase (II)≤5 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesNeurologyOncology

Familial Mediterranean Fever: On-Demand Anakinra Treatment

We are studying whether on-demand Anakinra can help patients with colchicine-resistant FMF manage painful attacks without daily therapy. This trial compares its effectiveness to standard pain management options.

Familial Mediterranean Fever>2 yearsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesPartially RemoteHematologyInfectious DiseasesInternal MedicineRheumatology

Stroke Treatment: Intra-Arterial Thrombolysis Study

We are studying whether adding a specific clot-dissolving treatment helps improve recovery in patients with acute strokes who have already had successful blood flow restoration. This trial will also evaluate safety and costs associated with this treatment.

Ischemic Stroke1-2 yearsConfirmation phase (III)≤5 visitsNo PlaceboInvestigational MedicinesPartially RemoteCardiologyNeurology

Bone Health: Identifying Risks from Glucocorticoids

We are studying how to find biomarkers that indicate a risk of bone disease in people taking glucocorticoids. This research may help improve monitoring and prevention strategies for affected individuals.

Secondary Osteoporosis≤3 monthsEfficacy phase (II)≤5 visitsStandard MedicinesCost ReimbursementEndocrinologyRheumatology

Coronary Artery Disease: SYN2 PET Scan Study

We are testing a new tracer for PET scans to see if it helps diagnose coronary artery disease in patients who may have it. The study will also assess the safety of this new diagnostic method.

Coronary Artery Disease>2 yearsConfirmation phase (III)≤5 visitsNo PlaceboInvestigational MedicinesCardiology

Viral Lung Infection: Tozorakimab Study

We are testing the new medication tozorakimab in patients hospitalized for viral lung infections requiring oxygen. The goal is to see if it can help prevent serious complications compared to a placebo.

Acute Respiratory FailureSevere Viral Lung Infections≤3 monthsConfirmation phase (III)≤5 visitsInvestigational MedicinesCost ReimbursementPartially RemoteInternal MedicinePulmonology